182495-99-4

Basic information

• Product Name: 3'-O-acetyl-2'-O-methoxyethyl-5'-O-(4,4'-dimethoxytrityl)-5-methyl-4-triazoleuridine
• Synonyms: 3'-O-acetyl-2'-O-methoxyethyl-5'-O-(4,4'-dimethoxytrityl)-5-methyl-4-triazoleuridine
• CAS NO: 182495-99-4
• Molecular Weight: 711.772
• Mol File: 182495-99-4.mol

Chemical Properties

• CAS DataBase Reference: 3'-O-acetyl-2'-O-methoxyethyl-5'-O-(4,4'-dimethoxytrityl)-5-methyl-4-triazoleuridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-O-acetyl-2'-O-methoxyethyl-5'-O-(4,4'-dimethoxytrityl)-5-methyl-4-triazoleuridine(182495-99-4)
• EPA Substance Registry System: 3'-O-acetyl-2'-O-methoxyethyl-5'-O-(4,4'-dimethoxytrityl)-5-methyl-4-triazoleuridine(182495-99-4)

Safety Data

• Hazardous Substances Data: 182495-99-4(Hazardous Substances Data)

Upstream product

• 288-88-0 1,2,4-Triazole 
• 182495-98-3 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine 
• 288-36-8 1,2,3-triazole 
• 163759-50-0 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine 

Downstream Products

• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 

Relevant articles and documents

Commercial-scale synthesis of protected 2′-deoxycytidine and cytidine nucleosides

Transformation of 2′-deoxyuridine and uridine analogs to protected 2′-deoxycytidine and cytidine analogs has been investigated by two different methods. First, traditional triazolation protocol and second p-nitrophenoxylation method. Our studies conclude

Antisense modulation of histone deacetylase 4 expression

Antisense compounds, compositions and methods are provided for modulating the expression of Histone deacetylase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Histone deacetylase 4. Methods of using these compounds for modulation of Histone deacetylase 4 expression and for treatment of diseases associated with expression of Histone deacetylase 4 are provided.

Antisense modulation of CDC14A expression

Antisense compounds, compositions and methods are provided for modulating the expression of CDC14A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CDC14A. Methods of using these compounds for modulation of CDC14A expression and for treatment of diseases associated with expression of CDC14A are provided.

Antisense modulation of CD36 expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD36. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD36. Methods of using these compounds for modulation of CD36 expression and for treatment of diseases associated with expression of CD36 are provided.

Antisense modulation of Notch (Drosophila) homolog 4 expression

Antisense compounds, compositions and methods are provided for modulating the expression of Notch (Drosophila) homolog 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Notch (Drosophila) homolog 4. Methods of using these compounds for modulation of Notch (Drosophila) homolog 4 expression and for treatment of diseases associated with expression of Notch (Drosophila) homolog 4 are provided.

Antisense modulation of histone deacetylase I expression

Antisense compounds, compositions and methods are provided for modulating the expression of Histone deacetylase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Histone deacetylase 1. Methods of using these compounds for modulation of Histone deacetylase 1 expression and for treatment of diseases associated with expression of Histone deacetylase 1 are provided.

Antisense modulation of GFAT expression

Antisense compounds, compositions, and methods are provided for modulating the expression of Glutamine-fructose-6-phosphate amidotransferase (GFAT). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding GFAT. Methods of using these compounds for modulation of GFAT expression and for treatment of diseases associated with expression of GFAT are provided.

Antisense modulation of histone deacetylase 4 expression

Antisense compounds, compositions and methods are provided for modulating the expression of Histone deacetylase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Histone deacetylase 4. Methods of using these compounds for modulation of Histone deacetylase 4 expression and for treatment of diseases associated with expression of Histone deacetylase 4 are provided.